HHS Nominee Kennedy’s Behind-The-Scenes Vaccine Reassurances Win Senate Swing Vote

Outreach by Kennedy and the Trump Administration appears to have quelled Sen. Cassidy’s fears about oversight of vaccine regulations and safety monitoring.

A sign outside Louisiana Republican senator Bill Cassidy's office in Washington DC.
Cassidy's support for Kennedy's nomination for HHS secretary likely paves the way for Senate approval. (Shutterstock)

US Health and Human Services Department Secretary nominee Robert F. Kennedy Jr.’s commitments on his approach to vaccines and his willingness to forge an “unprecedented” collaboration with Sen. Bill Cassidy, R-LA, enabled the nomination to advance toward final confirmation.

More from Vaccines

Peter Marks Resigns From US FDA, Warns Kennedy Does Not Want Truth On Vaccines

 

In his resignation letter, the CBER director said he was willing to work with HHS Secretary Robert F. Kennedy Jr. to address concerns about vaccine safety, but "it has become clear that truth and transparency are not desired by the secretary."

‘Pipeline In A Pill’ Or Pipe Dream? US FDA’s April Goal Dates Test Expansion Strategies

 

Sanofi’s Dupixent, Amgen’s Uplizna, and Bristol’s Opdivo seek new indications, while J&J hopes to start a franchise with nipocalimab and Stealth’s day of reckoning approaches.

US CDC Vaccines AdComm Rescheduled For April Without Influenza Vote

 

The disruption of CDC’s Advisory Committee on Immunization Practices meeting schedule adds fuel to concerns about potential alterations of the vaccine schedule raised by former FDA Commissioner Scott Gottlieb.

Almost Public: Interagency Meeting Replaces US FDA ‘25-’26 Flu Vaccine AdComm

 

Only government staff participated in the meeting defining the next season’s influenza vaccine composition after the annual public FDA vaccines advisory committee meeting was cancelled.

More from Geography

EMA Recommends EU Approval For Averoa’s Xoanacyl And Four Other Drugs

 

The European Medicines Agency has recommended five drugs for EU-wide approval , including Averoa’s Xoanacyl for concomitant hyperphosphatemia. Two companies have withdrawn their marketing authorization applications.

European Regulator Deals Blow For Lilly’s Alzheimer’s Drug Kisunla

 

Eli Lilly’ will request a re-examination after the European Medicines Agency declined to recommend its Alzheimer’s disease drug Kisunla for EU approval.

Recent And Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.